

Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update

Alligator Bioscience (Nasdaq Stockholm: ATORX) - On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report for the year ended 31 December 2018. All interested parties are invited to participate in a telephone conference, which will include a presentation of the Year-end Report, on the same day at 09:00 a.m. CET. The event will be hosted by CEO Per Norlén and the presentation will be held in English.

When: 09:00 a.m. CET Thursday 14 February 2019

Listen to the presentation: <https://financialhearings.com/event/11461>

To participate in the telephone conference, please use the dial in details shown below:

SE: +46856642692

UK: +443333009266

US: +18338230590

The conference call will be made available on the company's website after the call:

<http://www.alligatorbioscience.com>.

For further information, please contact:

Cecilia Hofvander, Director Investor Relations & Communications

Phone +46 46 540 82 06

E-mail: cecilia.hofvander@alligatorbioscience.com

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immunoncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has 50+ employees. For more information, please visit www.alligatorbioscience.com.

ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.